These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28447440)

  • 21. Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study.
    Kishimoto S; Higashi Y; Imai T; Eguchi K; Fukumoto K; Tomiyama H; Maemura K; Tanaka A; Node K;
    Cardiovasc Diabetol; 2023 May; 22(1):119. PubMed ID: 37210524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study.
    Ito D; Inoue K; Sumita T; Hamaguchi K; Kaneko K; Yanagisawa M; Inukai K; Inoue I; Noda M; Shimada A
    J Clin Med Res; 2018 Sep; 10(9):679-687. PubMed ID: 30116437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin.
    Kato M; Sakai K; Saito K; Tsutsui K; Yamashita S; Kato N
    Diabetol Int; 2017 Aug; 8(3):275-285. PubMed ID: 30603333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring.
    Kawaguchi Y; Sawa J; Kumeda Y
    Diabetes Ther; 2020 Dec; 11(12):2945-2958. PubMed ID: 33063270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.
    Ito D; Shimizu S; Haisa A; Yanagisawa S; Inoue K; Saito D; Sumita T; Yanagisawa M; Uchida Y; Inukai K; Shimada A
    J Diabetes Investig; 2024 May; ():. PubMed ID: 38775319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor.
    Tezuka Y; Sekine O; Hirano A; Hanada Y; Nakanishi I; Ariga M; Azuma C; Yamamoto Y; Ito-Kobayashi J; Washiyama M; Iwanishi M; Furuta M; Kanamori M; Shimatsu A; Kashiwagi A
    Diabetes Ther; 2021 Jan; 12(1):431-440. PubMed ID: 33108650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 May; 12(5):1359-1378. PubMed ID: 33730336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Tobe K; Maegawa H; Nakamura I; Uno S
    Diabetol Int; 2021 Apr; 12(2):181-196. PubMed ID: 33786273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus.
    Bando Y; Ogawa A; Ishikura K; Kanehara H; Hisada A; Notumata K; Okafuji K; Toya D
    Diabetol Int; 2017 Jun; 8(2):218-227. PubMed ID: 30603325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study.
    Okada J; Yamada E; Okada K; Okada S; Yamada M
    Curr Ther Res Clin Exp; 2020; 93():100597. PubMed ID: 32874375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus.
    Takase T; Nakamura A; Yamamoto C; Atsumi T; Miyoshi H
    Expert Opin Pharmacother; 2018 May; 19(7):631-632. PubMed ID: 29591723
    [No Abstract]   [Full Text] [Related]  

  • 32. Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?
    Pafili K; Maltezos E; Papanas N
    Expert Opin Pharmacother; 2018 Feb; 19(3):185-187. PubMed ID: 29202593
    [No Abstract]   [Full Text] [Related]  

  • 33. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 Oct; 12(10):2801-2805. PubMed ID: 34463953
    [No Abstract]   [Full Text] [Related]  

  • 34. Correction to: Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.
    Nakamura I; Maegawa H; Tobe K; Uno S
    Diabetes Ther; 2021 Jun; 12(6):1765-1768. PubMed ID: 34018149
    [No Abstract]   [Full Text] [Related]  

  • 35. Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Mar; 8(3):267. PubMed ID: 26858805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishikawa T; Kobayashi K; Takemoto M; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Tatsuno I; Terano T; Hashimoto N; Kuribayashi N; Uchida D; Yokote K;
    BMJ Open; 2017 May; 7(5):e015766. PubMed ID: 28490565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2017 Aug; 809():163-171. PubMed ID: 28506912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
    Gantz I; Okamoto T; Ito Y; Okuyama K; O'Neill EA; Kaufman KD; Engel SS; Lai E;
    Diabetes Obes Metab; 2017 Nov; 19(11):1602-1609. PubMed ID: 28449368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.
    Yang XL; Duo-Ji MM; Long ZW
    J Cell Biochem; 2017 Dec; 118(12):4536-4547. PubMed ID: 28471499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.